573 related articles for article (PubMed ID: 26565430)
1. Proteomic Approaches for Biomarker Panels in Cancer.
Tanase C; Albulescu R; Neagu M
J Immunoassay Immunochem; 2016; 37(1):1-15. PubMed ID: 26565430
[TBL] [Abstract][Full Text] [Related]
2. Oncoproteomics: Trials and tribulations.
Zhou L; Li Q; Wang J; Huang C; Nice EC
Proteomics Clin Appl; 2016 Apr; 10(4):516-31. PubMed ID: 26518147
[TBL] [Abstract][Full Text] [Related]
3. Mass spectrometry based translational proteomics for biomarker discovery and application in colorectal cancer.
Ma H; Chen G; Guo M
Proteomics Clin Appl; 2016 Apr; 10(4):503-15. PubMed ID: 26616366
[TBL] [Abstract][Full Text] [Related]
4. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications.
Jimenez CR; Verheul HM
Am Soc Clin Oncol Educ Book; 2014; ():e504-10. PubMed ID: 24857147
[TBL] [Abstract][Full Text] [Related]
5. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
Yan Y; Zuo X; Wei D
Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.
Ummanni R; Mannsperger HA; Sonntag J; Oswald M; Sharma AK; König R; Korf U
Biochim Biophys Acta; 2014 May; 1844(5):950-9. PubMed ID: 24361481
[TBL] [Abstract][Full Text] [Related]
7. Cancer proteomics: developments in technology, clinical use and commercialization.
Yeat NC; Lin C; Sager M; Lin J
Expert Rev Proteomics; 2015 Aug; 12(4):391-405. PubMed ID: 26145529
[TBL] [Abstract][Full Text] [Related]
8. Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach.
Ali M; Khan SA; Wennerberg K; Aittokallio T
Bioinformatics; 2018 Apr; 34(8):1353-1362. PubMed ID: 29186355
[TBL] [Abstract][Full Text] [Related]
9. Clinical proteomics and mass spectrometry profiling for cancer detection.
Solassol J; Jacot W; Lhermitte L; Boulle N; Maudelonde T; Mangé A
Expert Rev Proteomics; 2006 Jun; 3(3):311-20. PubMed ID: 16771703
[TBL] [Abstract][Full Text] [Related]
10. Proteomics discovery of radioresistant cancer biomarkers for radiotherapy.
Chang L; Graham P; Hao J; Bucci J; Malouf D; Gillatt D; Li Y
Cancer Lett; 2015 Dec; 369(2):289-97. PubMed ID: 26427840
[TBL] [Abstract][Full Text] [Related]
11. Circulating biomarker panels for targeted therapy in brain tumors.
Tanase C; Albulescu R; Codrici E; Popescu ID; Mihai S; Enciu AM; Cruceru ML; Popa AC; Neagu AI; Necula LG; Mambet C; Neagu M
Future Oncol; 2015; 11(3):511-24. PubMed ID: 25241806
[TBL] [Abstract][Full Text] [Related]
12. Rational design of cancer gene panels with OncoPaD.
Rubio-Perez C; Deu-Pons J; Tamborero D; Lopez-Bigas N; Gonzalez-Perez A
Genome Med; 2016 Oct; 8(1):98. PubMed ID: 27716338
[TBL] [Abstract][Full Text] [Related]
13. The ongoing evolution of proteomics in malignancy.
Dhamoon AS; Kohn EC; Azad NS
Drug Discov Today; 2007 Sep; 12(17-18):700-8. PubMed ID: 17826682
[TBL] [Abstract][Full Text] [Related]
14. The molecular make-up of a tumour: proteomics in cancer research.
Kolch W; Mischak H; Pitt AR
Clin Sci (Lond); 2005 May; 108(5):369-83. PubMed ID: 15831087
[TBL] [Abstract][Full Text] [Related]
15. Biomarker discovery by proteomics-based approaches for early detection and personalized medicine in colorectal cancer.
Corbo C; Cevenini A; Salvatore F
Proteomics Clin Appl; 2017 May; 11(5-6):. PubMed ID: 28019089
[TBL] [Abstract][Full Text] [Related]
16. Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective.
Findeisen P; Neumaier M
Clin Chem Lab Med; 2009; 47(6):666-84. PubMed ID: 19445650
[TBL] [Abstract][Full Text] [Related]
17. Proteogenomics for understanding oncology: recent advances and future prospects.
Subbannayya Y; Pinto SM; Gowda H; Prasad TS
Expert Rev Proteomics; 2016; 13(3):297-308. PubMed ID: 26697917
[TBL] [Abstract][Full Text] [Related]
18. Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management.
Stepczynska A; Schanstra JP; Mischak H
Bioanalysis; 2016; 8(5):439-55. PubMed ID: 26891752
[TBL] [Abstract][Full Text] [Related]
19. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.
Fredolini C; Liotta LA; Petricoin EF
Crit Rev Clin Lab Sci; 2010; 47(3):125-38. PubMed ID: 20858067
[TBL] [Abstract][Full Text] [Related]
20. Protein arrays for biomarker discovery.
Reid JD; Parker CE; Borchers CH
Curr Opin Mol Ther; 2007 Jun; 9(3):216-21. PubMed ID: 17608019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
